Drug Profile
Dimdazenil - Evotec/Zhejiang Jingxin Pharmaceutical
Alternative Names: EVT-201Latest Information Update: 05 Dec 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer Evotec SE; Zhejiang Jingxin Pharmaceutical
- Class Benzodiazepines; Chlorobenzenes; Dimethylamines; Imidazoles; Ketones; Oxadiazoles; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Registered Insomnia
Most Recent Events
- 29 Nov 2023 Registered for Insomnia in China (PO) - First global approval
- 24 Oct 2023 Efficacy and adverse events data from a phase III trial in Insomnia released by Zhejiang Jingxin Pharmaceutical
- 21 Oct 2023 Efficacy and adverse events data from a phase II trial in Insomnia released by Zhejiang Jingxin Pharmaceutical